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ABSTRACT 
 
Staphylococcus aureus produces a large number of proteins that specifically bind to molecules from plasma or 
from the human extracellular matrix where they are involved in processes associated with the colonization of the 
host tissues. At least six different fibrinogen-binding proteins have been identified from S. aureus; Clumping 
factor A and B (ClfA and ClfB), Coagulase, Efb (previously Fib), FbpA , Map and Eap. This work focuses 
primarily on the function(s) of Efb and Eap. 
 
We have shown that Efb contributes to the virulence of S. aureus in wound infection. An allele replacement 
mutant of Efb was constructed and compared with the virulence of the wild type in a rat model of wound 
infection. Sixty-seven % of the animals challenged with the parental strain developed severe clinical signs of 
wound infection, whereas only 29 % of the rats infected with the isogenic mutant showed severe symptoms. The 
function of Efb in infection is unclear but we have shown in vitro that multiple binding sites are involved in the 
interaction between Efb and fibrinogen. One binding site is located at the C terminus of Efb and one binding site 
at the two repeat regions of the N terminus. These N-terminal repeats are homologous to those at the C terminus 
of coagulase. The divalent binding nature of Efb with Fg leads to the precipitation of the Efb-fibrinogen 
complex, which can be enhanced by Ca2+ or Zn 2+ but not by Mg2+. At least one of the binding sites for Efb is 
located at the Aα-chain of Fg (Aα 111 - Aα 197). Binding of Efb to this  site may serve to block specific Aα-
chain processes. In addition, we have shown that Efb could bind to fibrin as well as to fibrinogen and that the 
two repeats of Efb could compete with the five repeats of coagulase for the same binding domain on fibrinogen.  
 
We have shown in this study that Eap (extracellular adherence protein) have the ability to enhance the  
adherence of Staphylococcus aureus to host cells. Eap can bind at least seven plasma proteins, including  
fibrinogen, prothrombin and fibronectin. Eap is presumably the same, or at least related to a previously 
described cell surface protein, designated Map for major histocompatibility complex class II analogous protein. 
In contrast to Map, Eap is mainly extracellular since 70% of the protein was found in the culture supernatant of 
S. aureus strain Newman. In this study we proposed a novel mechanism for adherence of S. aureus to host 
components stimulated and mediated by Eap. This is based on the fact that; i) Eap can form olimeric forms ii) 
Staphylococcus aureus strain Newman adhere to immobilized and soluble Eap, but not to the other 
staphylococcal proteins tested iii) Eap was  able to cause agglutination of Staphylococcus aureus and iv) 
Attachment of S. aureus  to fibroblasts and epithelial cells was significantly enhanced by the presence of Eap. 
In conclusion, Staphylococcus aureus produce several fibrinogen-binding proteins that interact with fibrinogen 
in different ways. Colonization of the host tissues and dissemination of the infection is a multifactorial event in 
which many extracellular and cellsurface proteins are involved. FgBPs play an important role during infection 
by: a) A cellsurface FgBP that mediates the direct attachment of S. aureus to damaged heart valves and 
implanted biomaterial,  b) A secreted FgBP with broad binding specificity that promotes colonisation of host 
tissues and bacterial aggregation, and c) A 15.9 kDa secreted FgBP that influences the severity of a wound 
infected by S. aureus thereby altering the healing process. 
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INTRODUCTION 
 
General background about S. aureus 
The family Micrococcaceae consists of four genera: Planococcus, Stomatococcus, 
Micrococcus and Staphylococcus the latter of which is the only genus of medical importance 
in this family. Staphylococci which infect humans include 13 coagulase - negative species 
(CNS) including S.epidermidis, S. capitis, S. saccharolyticus, S. warneri, S. haemolyticus, S. 
hominis, S.lugdunensis, S. schleiferi, S. auricularis, S. saprophyticus, S. cohnii, S. xylosus and 
S.simulans and one coagulase - positive species, S. aureus. Other species of coagulase 
positive staphylococci have been recognised in different mammals as S. intermedius in dogs, 
S.hyicus in pigs and S. delphini in dolphins (48). 
 
Staphylococci are non-motile, Gram-positive, catalase-positive, facultative anaerobic cocci 
usually arranged in irregular clusters. Robert Koch was the first to describe staphylococci in 
human pus. Later Alexander Ogston introduced the name Staphylococcus from the Greek 
word staphyle meaning ”bunch of grapes” (70). Two staphylococcal species were discribed 
by Rosenbach in 1884 based on the pigmentation of the colonies (79): Staphylococcus aureus 
with golden yellow colonies and Staphylococcus albus with white colonies, whose name was 
later changed to Staphylococcus  epidermidis.  
 
Diseases caused by S. aureus 
Today, 49 years after the introduction of penicillin, staphylococci continue to plague humans 
and animals. This microorganism under certain circunstances can easily be converted  to a 
pathogen which infects immunocompromised patients as well as healthy individuals causing 
both hospital- and community acquired infections. With its broad tropism for host tissues, this 
pathogen can colonize many different parts of the body (heart valve, lungs, skin and bones) 
demonstrating adaptibility and ability to disseminate.  
 
The list of diseases caused by Staphylococcus aureus is long (Table I) and includes a range of 
infections from soft tissue infections to severe, life threating debilitations. The most simple 
infection, folliculitis, is a pyogenic infection localized to the hair follicle. Staphylococcal 
wound infections often follow surgery or traumatic injuries. In USA, 25% of nosocomial 
infections are post-operative wound infections, 20-30% of which are caused by S. aureus 
(27). From local skin infections, the organism can enter the blood stream causing septicemia. 
Septicemia can be a serious condition, often acquired in the hospital either in association with 
implanted medical devices or during post-operative recovery. 
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Staphylococci in septicemia are easily disseminated causing metastatic infections such as 
osteomylitis. Osteomylitis is an infection of the bone which can result from hematogenous 
spreading of bacteria or from the direct introduction of microorganism from external sources 
as in trauma. S. aureus is the most frequent cause of osteomyelitis. In children the infection 
involves the metaphyseal area of the long bones, whereas osteomyelitis in adults commonly 
involves the vertebrae of the spine.  
 
Another type of staphylococcal dissemination is infective endocarditis which is an infection 
of a heart valve usually characterized by a vegetation on the aortic valve. Acute endocarditis 
caused by S. aureus is a serous disease with a mortality rate of 50 %.  S. aureus is responsible 
for about 30 percent of cases of native valve endocarditis (NVE) and 50% of endocarditis in 
intravenous drug users whose disease normally involve the tricuspid valve at the right side of 
the heart. Rheumatic fever, congenital cardiac defect, degenerative valvular disease, previous 
endocarditis and prosthetic valves are predisposing factors for infective endocarditis. 
 
 
 
Table I. Diseases caused by Staphylococcus aureus. 
INFECTION HOST TISSUE INTOXICATION HOST TISSUE 
Wound infections Skin Food poisoning Intestinal epithelial cells 
Folliculitis Hair follicle Scalded skin syndrome  
Septicaemia Blood Toxic shock syndrome  
Endocarditis Heart valve   
Osteomyelitis Bone   
Arthritis Joint   
Pneumonia Lung   
Mastitis Mammary glands   
 
 
 
S. aureus can also cause infections in animals.  For example, this pathogen is the leading 
cause of intramammary infection in cattle and is the most economically important disease in 
the dairy industry. Mastitis accounts for approximately 70% of the total expenses for dairy 
farms resulting in the loss of billions of dollar in the USA. In addition, Staphylococus aureus 
can cause pneumonia, impetigo, food poisoning and toxic shock syndrome. 
 
A major problem in the treatment of staphylococcal disease has been the increase of 
methicillin-resistant S. aureus (MRSA) strains in many countries including  Japan, Denmark 
FIBRINOGEN-BINDING PROTEINS FROM STAPHYLOCOCCUS AUREUS                                                              11
and countries of southern Europe.  After the introduction of methicillin in the 1960’s, the 
incidence of MRSA has grown significantly. The most likely explanation for this appearance 
and spread of MRSA is the increased use and abuse of broad spectrum antibiotics. Certain 
strains of MRSA, the so called multiresistent types, not only have developed resistance to 
methicillin but also to most other antibiotics with the exception of vancomycin.  The future 
emergence of vancomycin-resistant strains could be disastrous. Consequently, rapid 
diagnosis, restricted use of antibiotics  and new alternative treatments are urgently needed. 
 
Virulence factors associated with S. aureus 
Staphylococcus aureus produces virulence factors that participate. i) in the bacterial 
attachment to host components, ii) in the evasion of host defences and iii) the spread to distal 
or deeper tissues. 
 
i) Staphylococcus aureus attaches to components of the cell surface or to the extracellular 
matrixes as one of the first steps in the colonization of the host tissues. A family of adhesins 
called ECMBP (extracellular matrix binding proteins)(Table II) recognize specific host matrix 
proteins such as fibronectin (Fn) (21, 39), collagen (Co) (74, 89, 90), elastin (56, 72) and bone 
sialo protein (80). Certain plasma proteins including fibrinogen (Fg) (9, 60), prothrombin (Pt) 
(10, 77), vitronectin (Vn) (55, 75), thrombospondin (33) and plasminogen (Pl) (50, 81) are 
also recognized. Most ECMBP are attached to the staphylococcal cell wall by a common 
mechanism, the LPXTG sequence.  LPXTG is cleaved between threonine and glycine by 
sortase.  The threonine is then covalently linked to a pentaglycine bridge of uncross-linked 
peptidoglycan. However, cell surface associated Map and elastin-binding protein lack the 
LPXTG motif indicating that there are also other mechanisms in gram positive bacteria that 
anchor the protein to the cell wall.  
 
The most well characterized of the ECMBP are the two fibronectin-binding proteins (FnBPA 
and FnBPB), collagen-binding  protein (Cna) and clumping factor (Clf).  The FnBPs mediate 
colonization to various sites in the body where fibronectin is present especially in damaged 
heart valves and implanted medical devices.  Studies with double mutants in the fnbA fnbB 
genes indicate that fibronectin-binding is important in bacterial attachment to biomaterials 
which have been in contact with the blood (26). Other adhesins such as FgBP seem to be 
important in the adherence to biomaterial which have been in contact with the blood for less 
than 60 minutes (93). Discrepant results have been reported where a FnBP defective mutant 
was studied in an animal model of infective endocarditis. One of study demonstrated that the 
isogenic mutant reduced adherence to valvular vegetations (52).  However these results were 
not replicated in a second study (22). Collagen recognition in Staphylococcus aureus is 
mediated by a surface collagen-binding protein called Cna. That collagen-binding plays a role 
in infection was demonstrated in a septic arthritis model using a mutant deficient in Cna (73). 
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A Clf surface-associated protein is responsible for direct binding of staphylococcal cells to 
fibrinogen and fibrin (see the special section about FgBPs). 
 
 
Table II.  List of ECMBPs from Staphylococcus aureus 
ADHESIN MW (KDA) HOST MOLECULE REFERENCES 
ClfA  
ClfB 
92 (190)  
124 
Fibrinogen McDevitt et al., 1992 
Ní Eidhin et al., 1998 
Map 72 or 60 Fibrinogen 
Fibronectin 
Vitronectin  
Elastin. 
Homonylo McGavin et al., 1993 
FbpA 70 Fibrinogen Cheung et al., 1995 
FnBPA  
FnBPB 
108 
98 
Fibronectin Jönsson et al., 1991 
Greene et al., 1995 
Cna 135, 110 Collagen Switalski et al., 1989, 1993 
VnBP 60 Vitronectin   
Heparin 
Liang, Flock & Wadström, 1995 
Bone sialo protein 
-binding protein 
97 Bone sialo protein Rydén et al., 1989 
Thrombospondin-
binding protein 
 Thrombospondin Hermann et al., 1991 
EbpS 44 Elastin Park et al., 1991, 1996 
Staphylokinase  Plasminogen Sako et al., 1983 
Laminin-binding 
protein 
52 Laminin Lopes, dos Reis & Lowy, 1996 
 
 
 
ii) Staphylococcus aureus produces factors that are important in the microorganisms defense 
against  antibodies and phagocytosis. Several proteases from this organism such as the serine 
protease V8 have the ability to cleave and inactivate IgG and thus have a direct effect on 
specific antimicrobial peptides like the neutrophil defensins.  
 
Another group of proteins that participate in staphylococcal defence are the superantigens 
(including enterotoxins A to E, TSST-1 and the exfoliative toxin A and B).  These 
superantigens interfere with the immune process by binding to major histocompatibility 
complex class II (MHC II) and the variable region of the T-cell receptor β-chain. This 
activates T - lymphocytes expressing a particular T-cell receptor, leading to the release of 
relatively large quantities of cytokines.  Superantigens are antigens that do not require 
phagocytic processing. It is likely that these toxins prevent the host from producing antibodies 
to staphylococcal antigens during the course of an infection.  
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Protein A is a cell surface protein that binds to the Fc portion of IgG antibodies such that the 
antibodies that are misaligned thus interfering with the binding of phagocytic cells to IgG. 
Staphylococcal cells coated with antibodies evade the immune response and prevent 
opsonization. This was was confirmed using a protein A deficient mutant (Spa-) which 
showed that Spa- was taken up more efficiently by polymorphonuclear leucocytes than was 
the parental strain (25).  Complementary data demonstrated that Spa- mutant was less virulent 
than the wild type in a murine model of infection (23).   
 
The role of coagulase is unclear but it has been shown that this protein converts fibrinogen to 
fibrin forming a fiber layer around the bacteria. This layer probably shilds the organisms from 
phagocytosis. 
 
S. aureus is generally not considered to be an intracellular pathogen, but previous reports 
have shown that S. aureus cells can be internalized in nonprofessional phagocytes such as 
epithelial- (1) and endothelial cells (28). Bacteria induce internalization via a mechanism 
involving membrane pseudopod formation and the escape into the cytoplasm following lysis 
of the endosomal membrane.  Furthermore, internalization of  S. aureus can induce apoptosis 
in epithelial cells (7). Internalization provides protection against host defenses and antibiotic 
treatment, but how internalization occurs and which staphylococcal factors are involved is 
still unclear. 
 
iii) Staphylococcus aureus can secrete several proteins that facilitate the spread of the 
microorganism through tissue. Hemolysins are a group of molecules ( α-, β-, δ-, γ- toxins) 
that can damage the cytoplasmic membrane of the eukaryoric cells. For instance, α-toxin 
(alpha-haemolysin) can lyse several cells, including erythrocytes, leukocytes, hepatocytes, 
platelets and human diploid fibroblasts. Site directed mutagenesis of the hla gene has been 
used to study α-toxin. 
 
Hyaluronidas is an enzyme that digests hyaluronic acid, a component present in the matrix of 
connective tissues. This protein which is produced by 95-100 % of coagulase positive 
staphylococci and was previously referred to as a spreading factor. 
 
The list of staphylococcal virulence factors is long.  Staphylokinase, catalase, lipases, 
penicillinases, Toxic shock syndrome toxin-1 and exfoliative toxins are only a few exemples. 
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Fibrinogen-binding proteins from S. aureus 
Staphylococcus aureus interacts with fibrinogen  through both secreted and surface proteins. 
At least six different fibrinogen-binding  proteins have been identified from S. aureus so far; 
Clumping factor A and B (ClfA and ClfB), Coagulase (Coa), Efb (previously Fib), FbpA 
(surface-associated coagulase), Map and Eap (Table III). 
 
Extracellular fibrinogen-binding protein (Efb) 
Extracellular  fibrinogen-binding  protein, or Efb (previously known as Fib (9)) is a 15.9 kDa 
fibrinogen-binding  protein secreted by Staphylococcus aureus. Early studies showed that the 
efb gene and its gene product were found in all strain of S. aureus, but absent in other 
staphylococcal species such as S. epidermidis, S. hyicus, S. lugdunensis and S. intermedius, 
indicating that Efb is unique to S. aureus (12). Efb consists of 136 amino acids with no 
cystein residues and contains two nearly identical 22 amino acid segments at the N - terminal 
region which are similar to the fibrinogen-binding  domain of coagulase (11)(Figure 1).  No 
LPTXG amino acid sequence is found in Efb; a motif that is required for attachment of 
surface localized proteins to the cell wall. The predicted isoelectric point of 10.1-10.3 is due 
to its high lysine content which is about 14%.  
 
A mouse mastitis model was used to investigate the effect of immunization with Efb and 
collagen-binding  protein (Cna) against the staphylococcal infection.  Mice vaccinated with 
FgBPs showed a reduced rate of mastitis compared to controls vaccinated with CnBP.  
Furthermore, no pathological changes of the mammary glands were observed in the group 
vaccinated with FgBPs compared with an unvaccinated group. In addition, the number of 
bacteria recovered from the glands of the infected mice was significantly lower after FgBP 
immunization (57). 
 
In a recent study the antibody response to Efb was measured in patients with various 
staphylococcal infections (17). The antibody titer in the acute phase was significantly lower 
than the normal population.  In patients with arthritis and osteitis, the antibody response 
during the convalescent phase increased by 67 % compared to controls.  In patients with 
absceses,  a 50% increase above control levels was noted. The elevated response indicates 
that Efb is expressed and secreted in vivo by Staphylococcus aureus. 
 
Clumping factor. 
In 1908, Much (64) observed that staphylococcal cells from clinical isolates undergo 
clumping in the presence of plasma and easily form visible aggregations.  Fibrinogen is 
unique among the plasma proteins in being able to stimulate clumping in certain strains of 
Staphylococcus aureus. It was originally believed that the clumping factor was coagulase 
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which is situated on the bacterial cell surface. But later it was demonstrated that the 
agglutination of staphylococcal cells is associated with the cell wall protein clumping factor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
(Clf).  That this is not the case was demonstrated using an allele replaced S. aureus mutant 
defective in the coagulase gene (62). This mutant was deficient in coagulase activity but still 
interacted with fibrinogen indicating that the bound form of coagulase is not responsible for 
clumping and for the adherence of Staphylococcus aureus to solid phase fibrinogen.  
 
The high affinity of fibrinogen for staphylococcal clumping factor was shown in earlier 
studies. At this time it was estimated that 2130 fibrinogen molecules bound with a 
dissociation constant (Kd) of  9.9 nM to a single staphylococcal cell from strain Newman (32). 
But further characterization of the interaction between a fusion protein that contains the 
fibrinogen-binding domain of ClfA and an immobilized fibrinogen  using a BIAcore 
biosensor yielded a Kd  of 0.51 ±0.19 µM (61). The differences of these affinity values can be 
explained in two ways: i) in the first study, S. aureus strain Newman expressed several FgBPs 
that can be found on the cell surface and may contribute to adhesion to fibrinogen, and ii) in 
the second study, fibrinogen coupling to chip lost its structure and binding capacity. 
  
Efb   Y47    N  I  L   E  F  NDGTF  E     Y  G   ARP    Q  FNKP68 
Coagulase        T457   G  I  R  E  Y  NDGTF  G     Y  E   ARP     R  FNKP 478 
                       Y484   N  V T  T  H  ANGQV  S     Y  G  ARP     T  YKKP 505 
 R R R R R 
   1                                                                                                      434                         
610
       R        R          
      1        17                 49                                      
136
Figure 1. Schematic drawing of coagulase and Efb. The second repeat of 
Efb has high homology with the repeats of coagulase. 
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A mutant defective in the fibrinogen receptor was isolated by transposon Tn917 mutagenesis  
in  S. aureus strain Newman (60). Using this approach, McDevitt and co-workers cloned and 
characterised the gene (clfA) which encoded the protein responsible for the clumping reaction. 
The ligand-binding domain of ClfA is a 218-residue segment located between residues 332-
550 in  Region A (60). This region recognizes the amino acid sequence 
GAKQAGDVHPAETEYDSLY (46, 88) in the carboxyl-terminal of the γ-chain of the 
fibrinogen monomer. This region corresponds to the region that binds to GPIIb-IIIa receptor 
on platelets (31). A potential calcium binding EF-hand like motif was identified between 
residues 310 and 321 of Region A. (69). In addition, a high degree of similarity was found 
between a region in the fibrinogen-binding site of ClfA which displays a cation-binding 
motif, (MIDAS motif) located in the I (A) domain of integrins. The MIDAS motif which 
binds Mg2+  helps to determine the correct structure of the binding domain and thus facilitates 
the interaction of ClfA with fibrinogen. Deletion mutagenesis and site-directed mutagenesis 
in both the EF-hand like motif or in the MIDAS motif resulted in a significant reduction in the 
affinity for native fibrinogen and for a fibrinogen γ-chain peptide. These data suggest that the 
ClfA protein interacts with fibrinogen through a mechanism similar to the platelet integrin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S S                     A                              R            W  
M
S S                     A                            R            W  
M
S S                    A                  B1      B2       R       W   
M
  S S                   A                 B1   B2  B3   B4   B5      R          W  
M
S S                   A                        B1   B2   B3        R       W  
M
ClfA 
ClfB 
SdrC 
SdrD 
SdrE 
Figure 2. Structural organization of ClfA, ClfB, SdrC, SdrD and SdrE. SS, signal sequence; 
A, unique nonrepetitive sequence; B, B-repeats with the EF-hand loops; R, repeated 
domains containing Ser-Asp residues; W, cell wall-spanning domain; M, hydrophobic 
membrane-spanning domain (Josefsson et al., 1998). 
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A second clumping factor, ClfB, which is encoded by a distinct gene (clfB) was recently 
demonstrated in S. aureus (67). The domain organization of ClfB is similar to ClfA including 
a signal sequence (region A), region R which is composed of Ser-Asp repeats, a 
peptidoglycan spanning region (W), an LPTXG motif, a hydrophobic membrane-spanning 
region and a short positively charged C-terminus (Figure 2).  The degree of sequence 
homology between ClfA and ClfB is 41% for the signal region, 36% for the anchoring 
domain and 26% for region A. The diversity in the A region may explain why ClfB 
recognizes a different domain on Fg than that which is recognized by ClfA. Furthermore, 
ClfB binds to the Aα- and Bβ-chains of Fg as opposed to ClfA which binds to the γ-chain. 
ClfB is only detectable during the early exponential phase of the bacterial growth compared 
with ClfA which is present at all stages. ClfB promotes binding to immobilized Fg and 
clumping only during the exponential-phase of the growth. ClfB like ClfA binds Ca2+. ClfB 
also has a MIDAS-like motif as well, however, it is located in a different position than the 
MIDAS-like motif on ClfA.  
 
In addition, a new subfamily of proteins from S. aureus (the Sdr subfamily) which function as 
clumping factors have recently been described (37) (Figure 2). Three members of this 
subfamily, SdrC, SdrD and SdrD, have been characterized and shown to have organizational 
and sequence similarities to ClfA and ClfB. But in constrast to ClfA and ClfB, Sdr proteins 
have an additional motif, a  B-motif, located between region A and region R. Each B-motif is 
composed of 110-113 residues with the number of motifs varying between 3 and 5 among the 
Sdr proteins. EF-hand motifs which bind Ca2+ have been found in each B-motif and are 
critical for the conformation of the Sdr protein. Furthermore, the amino acid sequence of 
region A of the Sdr proteins have only 20-30% homology with the same region on ClfA and 
ClfB suggesting  different binding properties and function compared to ClfA and ClfB. 
 
Clumping of S. aureus in plasma and staphylococcal adherence to fibrinogen substrata has 
been suggested as important virulence factors. Evidence that ClfA can contribute to the 
pathogenesis of  infection associated with implanted medical devices and with infective 
endocarditis has been presented (IE) previously (63). The biological  role of ClfA in vivo was 
demonstrated in a study where a clumping factor defective mutant was compared with the 
parental strain. This study showed that the mutant had up to 100 times lower affinity for 
fibrinogen and produced 50 % less endocarditis in rats with catheter-induced aortic 
vegetations compared to the parent strain. The infection rate was restored to that of the wild-
type when a copy of the wild type gene was inserted into the clfA mutant. In other studies, this 
mutant showed reduced adherence to blood-conditioned catheters that had been in contact 
with the host for period of less than one hour (93). 
 
MARCO PALMA 
18 
Fibrin is the major component of blood clots and fibrinogen is one of the major plasma 
proteins deposited on surface of implanted biomaterial (94). Several blood components, 
including fibrinogen have been implicated in promoting bacterial attachment to implanted 
materials. Fibrinogen probably initiates staphylococcal adherence to foreign surfaces.  But the 
adsortion of this molecule is only transient and is replaced by other plasma proteins at a later 
stage after Fg has been proteolytic degraded by plasmin (93). 
 
Coagulase  
The protein, Coagulase, is produced by Staphylococcus aureus which stimulates fibrinogen 
polymerization and the clotting of plasmas in several mammalian species. Coagulase  exerts 
its biological effects through the activation of prothrombin via a non enzymatic process. In 
this process, staphylocoagulase acts as an allosteric effector that changes the conformation of 
prothrombin in such a way that active binding centres are made accessible to fibrinogen (44). 
Functional studies with α-chymotrypsin generated fragments of coagulase have identified the 
biologically important regions of the protein involved in prothrombin-binding and the 
coagulase activity (43, 45). A 43 kDa fragment containing 324 amino acids located in the 
NH2 -terminal portion posesses both prothrombin and coagulase activity. This fragment binds 
strongly to the C-terminal region of human prothrombin (44) with a dissociation constant of 
1.7 nM compared to the intact staphylocoagulase of 0.49 nM.  Staphylocoagulase is classified 
into eight different serotypes based on variations in the N-terminal sequence (92). Variations 
in this region are related to the different affinities of coagulase for prothrombin. 
 
In addition to prothrombin-binding, coagulase can interact directly with fibrinogen (10). The 
region required for prothrombin- and fibrinogen-binding  are located on different parts of the 
coagulase molecule. A 177 residue segment of the carboxy terminal of coagulase has been 
implicated in fibrinogen-binding  as shown in a study where this fragment was fused to β-
galactosidase (62).  
 
The predicted molecular weights of the extracellular forms of staphylocoagulases vary 
depending on the number of tandem repeats of a 27-residue sequence at the carboxy terminus. 
For example, strain 8325-4  has a 69 kDa coagulase with five repeats (77), strain 213 has a 72 
kDa protein with six repeats (40) and strain BB 77 kDa protein with eight repeats (41). The 
87 kDa coagulase from strain Newman seems to be identical to the coagulase from strain 
8325-4, but its binding to prothrombin has not been established. 
 
Staphylocoagulase is mainly an extracellular protein but a certain amount can be found on the 
surface of staphylococci as well. A previous study demonstrated that a small population of 
coagulase molecules remain tightly bound to the staphylococcal cell wall. There is now 
evidence that staphylocoagulase exists in multiple forms. Thus, not only different strains 
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produce different forms of staphylocoagulase but the same strain may produce multiple 
forms.  
 
Table III. FgBPs from Staphylococcus aureus. 
PROTEIN LOCATION MW (KDA) REFERENCES 
ClfA  
ClfB 
Cell surface 90(190)  
125 
McDevitt et al., 1992 
Ni Eidhin et al., 1998 
FbpA Cell surface 70 Cheung et al., 1995 
Map Cell surface 72 or 60 Homonylo McGavin et al., 
1993 
Jönsson et al., 1995 
Efb (Fib) Extracellular 15,9 Bodén & Flock, 1989, 1994 
Palma et al., 1998  
Wade et al., 1998 
Coagulase Extracellular 87 Bodén & Flock, 1989 
 
Eap  Extracellular 60 Palma, Haggar & Flock, 1999 
 
 
 
The role of coagulase in virulence is unclear. Previously studies suggested that in vivo 
coagulase stimulates dissemination, intra-vascular coagulation and enhances tissue survival of 
cocci  by inhibiting phagocytosis. Several authors have investigated the action of 
staphylocoagulase in vivo and determined the intravenous lethal dose of staphylocoagulase 
for rabbits and mice (19). The pathological changes induced by purified staphylocoagulase in 
the laboratory animals was also studied previously (2).  Several reports have shown that 
coagulase deficient mutants are less virulent in a mouse model of infection (29, 36). The 
problem with these experiments is that the mutants were isolated after chemically-induced 
mutagenesis.  Thus, a loss of other possible virulence determining factors must be considered. 
A later study which compared the virulence of a  site-specific, coagulase-deficient mutant 
with the coagulase-positive parental strain DU 5808 in a rat endocarditis model concluded 
that there was no differences in virulence between these two strains (5). These data support 
previous results from a murine model of infection and mastitis which indicated that coagulase 
is not a virulence factor (77). However, it should be considered that some virulence factors 
may play important roles only in specific infections and probably have different functions in 
different infections. Recent studies on coagulase-deficient  mutants show that coagulase is 
important in hematogenous pulmonary infections (82). When mice are injected intravenous 
with Staphylococcus aureus enmeshed in agar beads, multiple lung abcesses surrounding the 
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pulmonary arterioles form.  These abcesses consisted of bacterial colonies encircled by fibrin 
filaments and surrounded by neutrophils and macrophages. Animals infected with the 
coagulase-deficient strain or other bacterial species did not display these symptoms. 
 
FbpA 
Cheung et al cloned and sequenced the gene for a cell surface fibrinogen-binding coagulase 
(FbpA) (16). The sequence of a 34 kDa identified protein was identified containing a unique 
stretch of 11 amino acids between residues 409 and 419 (SVTLPSITGES) which shares 
homology with a cell wall anchor motif (LPXTGX).  
 
Major Histocompatibility complex class II analogous protein (Map) 
Map was first described by Homonylo McGavin et al as a 72-kDa surface protein that was 
capable of binding to fibrinogen and several other extracellular matrix proteins, including 
fibronectin, bone sialoprotein, vitronectin and thrombospondin (34). Later the gene coding 
this protein was cloned and sequenced (38). Map consists predominantly of six repeated 
domains of 110 residues each.  Each repeated domain contains a subdomain of 31 residues 
that share striking sequence homology with a segment in the peptide binding groove of the β 
chain of major histocompatibility complex (MHC) class II protein in different mammalian 
species. The interaction effects of Map and MCH II in infection are unknown. 
 
Influence of agr on FgBPs 
Very little is known about the regulation of the different FgBPs in S. aureus. Previous studies 
by Cheung and coworkers demonstrated that coa transcription was negatively modulated by 
agr and occurred mainly during the exponential growth phase. In contrast, clfA trancription 
was agr independent and was strongest during the postexponential phase (97). A triple mutant 
(agr, coa and clfA) showed decreased binding to Fg than the double mutant (agr and coa), but 
still retained some binding capacity. These data indicate that additional fibrinogen-binding 
components may be expressed such as ClfB, FbpA, Map, Eap or Efb.  
 
 
Fibrinogen-binding proteins from microorganisms other than S. aureus 
 
Fbe from S. epidermidis 
Staphylococcus epidermidis is an important cause of infections associated with medical 
devices as in prosthetic valve endocarditis, infections related with catheters or artificial joints. 
Immediately after implantation, biomaterials are covered with plasma proteins including 
fibrinogen which are targets of several strains of S. epidermidis (101). Baldassarri and 
coworkers reported that S. epidermidis slime-negative strains adhered significantly better to 
Fg than the slime positive strains (6). A fibrinogen-binding protein from S. epidermidis (Fbe) 
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has been identified on the surface of the bacterium.  Phage particles that bound specifically to 
immobilized fibrinogen were selected from a phage display library containing chromosal 
DNA from S. epidermidis (68). Fbe has the LPXTG motif and the predicted charged wall 
region usualy found in cell surface proteins on Gram positive bacteria.  Some similarity has 
been noted between the A region of ClfA and ClfB and  the region containing residues 295 to 
545 of Fbe. Furthermore, Fbe interacts with the β-chain of fibrinogen and Fbe-Fg binding can 
be stimulated by physiological concentrations of Ca2+ (76). 
 
M protein from S. pyogenes 
Streptococcus pyogenes is an important cause of pharyngitis, scarlet fever, streptococcal toxic 
shock syndrome, erysipelas, pyodermas and nonsuppurative sequelae such as acute rheumatic 
fever and glomerulonephritis. S. pyogenes recognizes and binds to plasma fibrinogen (51) 
with 8000-10000 fibrinogen-binding sites per bacterial cell (35). This interaction is associated 
with M protein (42), a fibrous protein located on the surface of the bacteria. 
 
The region located near the tips of M protein binds to the D fragment of Fg (96) with a 
dissociation constant of 10-9 to 10-7 M (35). M protein  is an important virulence factor of  S. 
pyogenes because of  its antiphagocytic capacity. Fibrinogen binds and covers streptococcal 
cells which inhibit the complement deposition on the bacterial surface, this allows the 
bacterium to evade opsonization (20).  
 
Other streptococcal components such as T protein (83) and G3PDH (71) also bind to Fg in a 
manner similar to M protein (86). 
  
Proteases from Bacteroides 
Bacteroides gingivalis and Bacteroides intermedius have been identified as causes of human 
periodontal diseases. Infections of this type are characterized by gingival inflammation 
accompanied by a loss of connective tissue and bone from around the roots of the teeth. P. 
gingivalis interacts with some Gram-positive bacteria such Actinomyces viscosus (84), 
Streptococcus gordonii (87), and Streptococcus oralis (66). This interaction may play an 
important role in the attachment and colonization of  P. gingivalis to periodontal sites.  It has 
been reported that fibrinogen is the most active inhibitor of P. gingivalis and S. oralis 
coaggregation. The inhibitory factor produced by Fg  has been localized to residues 158-176 
and 192-206 of the Aα-chain of fragment D which contains four and two arginine (65). Two 
different fibrinogen proteinases, Lys-gingipain (gingipain-K) and Arg-gingipain (gingipain-
R) have been identified in P. gingivalis. These proteinases degrade Fg so as to inhibit clot 
formation and thus increase bleeding at periodontitis sites. 
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Bacteroides gingivalis and Bacteroides intermedius bind with high affinity (Kd of 10 to 30 nM 
respectively) to different sites on fibrinogen (54). A 150 kDa cell surface protein from B. 
gingivalis recognises a region of fibrinogen located between the D and E domains and 
proteolytically degrades fibrinogen into two major components of 120 and 150 kDa (53).  
 
Cell surface protein from Candida 
Candida albicans is a part of the normal human flora but can cause opportunistic infections in 
immunocompromised hosts. It has been reported that this microorganism can also recognize 
human fibrinogen. A 68 kDa protein from the cell surface of this organism mediates  
attachment to the D-domain of Fg. The average number of binding sites per cell is estimated 
to be approximately 6000 with a dissociation constant of 5.2 x 10-8 M (3). 
 
Fibrinogen 
Fibrinogen, the precursor of fibrin, is a 340 kDa plasma glycoprotein which plays a major role 
in the process of blood clotting. Fibrinogen is arranged symetrically into three globular 
domains with one central domain (E) and two distal domains (D)(Figure 3). Each fibrinogen 
molecule consists of three pairs of non-identical polypeptide chains (AαΒβγ) arranged so that 
all six amino - termini are located in the central part of the molecule (18). The Aα-chains 
consists of 610 residues and has a molecular mass of 67 kDa. The Bβ-chain is a 55 kDa 
polypeptide composed of 461 residues and the 48 kDa γ-chain has 411 residues. Aα−, Bβ− 
and γ-chains are linked together in the central amino-terminal domain by three interchain 
disulfide  bridges.  
 
Tissue injury results in disruption of blood vessels which leads to the exposure and interaction 
of blood components with subendothelial structures. This triggers a series of reactions in 
which fibrinogen participates in the final stage. Thrombin cleaves Arg-Gly bonds in 
fibrinogen between Aα16 and 17 and between Bβ14 and 15 releasing fibrinopeptides A 
(FpA) (ADSGEGDFLAEGGVRGPRV) and B (FpB)(XGVNDNEEGFFSARGHRP), 
respectively (8). Fibrinopeptide A is released significantly faster than fibrinopeptide B under 
typical conditions. Only FpA is required for clot formation whereas FpB is chemotactic for 
human polymorphonuclear neutrophils and fibroblasts (85). FpA and FpB release exposes a 
binding site (49) in the E domain of Fg which subsequently aligns with a complementary site 
in the D domain of another molecule. The clot matrix is stabilized by the formation of 
covalent crosslinks between different molecules. Factor XIIIa which is a plasma 
transglutaminase catalyses the formation of isopeptide bonds between the γ-chains (15) and 
links the lysine at position 406 with a glutamine at position 398 or 399 of another γ-chain 
polypeptide.  
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Figure 3. Schematic drawing of fibrinogen. The dimeric molecule is composed of three 
polypeptide chains, α, β and γ. The binding sites for ClfA and GPIIb-IIIa are indicated on the 
fibrinogen molecule (including the RGD sequences). 
 
 
Platelet aggregation is a primary event in hemostasis and thrombus formation. Fibrinogen and 
fibrin contain several potential binding sites that interact with platelet GPIIb/IIIa receptors  
(31). One binding site (sequence HHLGGAKQAGDV) is located at the carboxy-terminus of 
the fibrinogen γ-chain (47). Other potential platelet GPIIb/IIIa binding site in Fg contain an 
Arg-Gly-Asp (RGD) sequence in the Aα95-97 and Aα572-574 regions (78).  However, the 
Aα-chain carboxy-terminus (Aα572 to 574) is not conserved between species as expected for 
a potential binding site, but the RGD at position Aα95 to 97 is conserved between species.  
Since the RGD - containing peptide found in certain snake venoms is a powerful inhibitor of 
the fibrinogen-binding  to platelets, at least one RGD site is essential for the Fg interaction 
with GPIIb-IIIa (30). 
 
Platelet aggregation can be reversible or irreversible. Reversible  aggregation  is mediated by 
the binding of fibrinogen to GPIIb-IIIa which occurs in the absence of secretion of the 
contents of platelet storage granules. In contrast, irreversible aggregation is secretion 
dependent. Thrombospondin is released in significant amounts by activated platelets and 
plays an important role in the stabilization of the fibrinogen platelet receptor interactions. 
Thrombospondin mediates irreversible platelet aggregation by binding to receptors on 
β-chain 
GPIIb-IIIa 
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platelets and to fibrinogen which is bound to glycoprotein GPIIb-IIIa. Thrombospondin binds 
specifically to Fg with a Kd of 3.4 nM. Thrombospondin binding sites on Fg are located at 
residues 113 to 126 of the Aα-chain and residues 243 to 252 of the Bβ-chain (4). 
It is well known that calcium is required for fibrinogen function since fibrin formation in the 
absence of calcium is significantly weaker then when it is formed in the presence of calcium.  
Three high affinity calcium binding sites  have been  determined for fibrinogen which have 
dissociation constants of Kd of 2 x 10 
-6 M (59). At least one of these is located at the C-
terminal region of the γ-chain which contains a putative sequence resembles an EF-hand, 
Ca2+-binding motif (DNDNDKFEGNC). Another site  was identified on the Aα-chain. 
Fibrinogen with an intact Aα-chain possesses three high-affinity binding sites but fibrinogen 
samples with partially degraded Aα-chain exhibited only two sites (58).       
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AIMS 
 
The aim of this study was to investigate FgBPs from Staphylococcus aureus, with the main 
focus on Efb (previously Fib) and on a 60 kDa fibrinogen- and prothrombin-binding protein. 
 
The specific aims were to: 
 
Construct an isogenic mutant deficient in Efb protein for subsequent comparison with the 
wild type in a rat infection model. 
 
Identification of fibrinogen-binding  sites on Efb and the regions on fibrinogen recognised by 
Efb.  
 
Characterization of the 60 kDa fibrinogen- and prothrombin-binding protein. 
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 METHODS 
 
Insertional inactivation of efb gene 
The use of mutations in genetic research are important tools for the determination of the 
specific functions of virulence factors. A mutation which is an alteration in the nucleotide 
sequence of DNA molecule is a spontaneous event in nature. In bacteria one mutation occurs 
spontaneously for every 108 cell divisions. Different methods have been developed for the 
construction of mutants and for the isolation of organisms carrying the defective genes of 
interest. For instance a mutation in a bacterial cell can be induced when the cells are exposed 
to chemical mutagens. This can result in a large number of mutants including a few with 
mutations in the desired genes. This approach has been used in several bacteriological studies 
where the chemical mutagens have affected more than one gene. Of course, such results are 
difficult to interpret because of the large number of nonspecific effects. For the construction 
of site-specific mutations in a single gene, better methods are now available such as allele-
replacement, transposon mutagenesis, plasmid integration and bacteriophage conversion. 
 
Allele replacement was used in study I for the construction of an isogenic mutant defective in 
the gene encoding the extracellular fibrinogen-binding protein, Efb. In principal, allele 
replacement consists of insertion of a DNA fragment encoding drug resistance into the gene 
for the virulence factor of interest. The point is to disrupt the integrity of the virulence gene 
with the DNA fragment. The inserted fragment blocks gene transcription and the drug 
resistance is used as a marker for the identification of the mutated cells. In our study, a 
fragment from transposon Tn4001 was used which contained the genes for gentamicin, 
kanamycin and tobramycin resistance. The efb gene was disrupted by this fragment in an 
unique XbaI site located upstream from the region responsible for fibrinogen-binding. Allele 
replacement consist of a substitution of  the wild-type allele with the mutated plasmid-located 
copy. One way to do this is by a double recombination between homologous sequences; for 
example between a mutated (efb::Gmr) and a wild-type copy of the efb gene.  
 
Techniques and strategies on how staphylococcal isogenic mutants can be constructed have 
been described before.  A suitable shuttle vector for this purpose which was used in this study 
is the vector pSPT181 which consist of the plasmids pSP64 and pRN8103. pRN8103 contains 
a determinant for temperature sensitive replication in S. aureus (a defect ORI) and the 
tetracycline resistance marker.  pSP64 contains an ampicillin-resistance marker and origin of 
replication for E. coli. This shuttle vector replicates in Gram-negative organisms such as E. 
coli and in a Gram-positive organisms like S. aureus. Replication of pSPT181 plasmid occurs 
in staphylococci at the permissive temperature (30oC), but not at the nonpermissive 
temperature (44oC).  
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When the shuttle plasmid with the mutated efb gene has been established at the permissive 
temperature in the presence of antibiotic, it is possible to find  a mixture of  cells whose 
plasmid are replicating autonomously (not integrated) and cells where the plasmid has been 
integrated into the chromosome. Integration occurs by a single Campbell-type recombination 
although recombination occurs only at one site of the efb gene. Such strains are not suitable 
for virulence studies because one copy of the gene is still intact. Allele-replacement occurs 
when a second recombination takes place on the other side of the efb gene. This event causes 
the loss of the integrated plasmid containing a copy of the intact efb gene while the mutated 
gene is retained in the chromosome. This recombination occurs at a low frequency and 
requires a special approach to select cells which carry the defective efb gene (Figure 4).  
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Figure 4. Strategy used for the construction and  selection of an isogenic mutant  
defective in the efb gene. 
 
I.  Selection for single recombination. First, the vector pPST181 containing the efb::Gmr copy 
replicate autonomously in S. aureus at the permissive temperature (32oC) in the presence 
of gentamicin and tetracycline. Under these conditions, the plasmid integrates into the 
chromosome by a single Campbell-type recombination in approximately 6 % of the cells, 
while the plasmids in the majority of the cells remain in an autonomous form. Cells with 
integrated plasmids may also have autonomously replicating plasmids. 
 
II. Selection for a double recombination. Cells with an integrated vector contain two copies 
of the efb gene on the chromosome (the mutated and the wild type one). A second 
recombination takes place between the two efb genes when the bacterial cells are grown at 
43oC in the presence of gentamicin. Depending on which side of the efb gene the first 
recombination had taken place, the plasmid excised from the chromosome will have either 
an intact or a mutated efb gene.Thus, those cells that have lost the efb::Gmr copy from the 
chromosome or those cells whose plasmid has never been integrated into the chromosome 
will be eliminated at 43oC in the presence of Gm.  These cells are unable to survive the 
antibiotic exposure since their plasmid containing the Gmr gene can not be replicate at this 
temperature. Conversly, those cells where the recombination has take place at the other 
side of the efb gene, lose the intact copy of the efb gene but retain the efb::Gmr  in the 
chromosome. 
                  
III. Amplification of the recombinant.  The proportion of cells that carry an integrated 
plasmid can be reduced during this step, at 43oC without antibiotic. Mutants defective in 
the efb gene can be now detected by replica plating on plates with Gm or Tc, since these 
mutants are gentamicin resistant and tetracycline sensitive.  
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Isolation of extracellular FgBPs from S. aureus 
Three  extracellular  fibrinogen-binding  proteins have been reported previously by Bodén 
and Flock. They described an 87 kDa coagulase produced mainly during the exponential 
growth phase which was later replaced by a 60 kDa fibrinogen- and prothrombin - binding 
protein during the post-exponential growth phase. The third protein identified was described 
as a 19 kDa FgBP constitutively produced by S .aureus which they called Fib. In later studies 
the name Fib was changed to Efb for extracellular fibrinogen binding protein (II) since in the 
litterature Fib is sometimes used as an abbreviation for Fg.  
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Figure 5.  Separation of the extracellular fibrinogen-binding proteins from S. aureus using 
FPLC on a Mono-S column. The FPLC profile revealed three peaks corresponding to the 
three FgBPs 
 
 
First, the fibrinogen-binding proteins were isolated from the culture supernatant of 
Staphylococcus aureus strain Newman by affinity chromatography on  fibrinogen-Sepharose. 
In studies II and V a further purification step was added consisting of ion exchange 
chromatography which was necessary for the separation of three FgBPs. A Mono-S column 
coupled with Fast protein liquid chromatography (FPLC) equipment was used and the three 
proteins were eluted using an NaCl gradient (Figure 5). The first peak contained a 60 kDa 
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degradation product of the 87 kDa coagulase. It has been also demonstrated before that the 
repeats from the C-terminal region of coagulase are sensitive to degradation. The second 
protein eluted was Efb and the third was a protein which binds both to Fg and Pt but lacks 
coagulase activity. This protein was called Eap for extracellular  adherence protein.  
 
Isolation of the Aα−-, Bβ−  and γ−  chains of  fibrinogen 
The most common method used for isolation of the chains of fibrinogen is the fractionation of 
the three polypeptides by ion exchange  chromatography on CM-cellulose after reduction of 
the interchain disulfide bridges. In study IV, we developed a new method for separation of the 
polypeptides chains.  This method consists of continuous-elution electrophoresis with a 
Model 491 Prep cell from Bio-Rad. Samples containing fibrinogen migrate 
electrophoretically through a 10 cm long cylindrical gel of 10% polyacrylamide. As the three 
chains migrate through the gel matrix, they are separated according to their molecular weight 
as with conventional gel electrophoresis. When individual bands migrate to the bottom of the 
gel,  they  pass directly into the elution chamber for collection. Purified molecules are drawn 
up through the elution collection tube by a peristaltic pump to a fraction collector. 
 
Digestion of fibrinogen by plasmin 
Proteolytic fragmentation of fibrinogen with plasmin has been used intensively in studies for 
the localization of functionally important sites on the fibrinogen molecule (IV). Digestion of 
Fg with plasmin yields a set of fragments designated A-E, according to their order of elution 
from a DEAE-cellulose column. Fragments A-C comprise a group of smaller peptides 
released during the course of digestion. Fragment D and E are the largest fragments generated 
during complete plasmid digestion of Fg (Figure 6). These fragments have masses of 50% and 
15% of the  fibrinogen molecule, respectively. Fragment D corresponds mainly to the distal 
domain and fragment E to the central domain. In addition, partial digestion of Fg with 
plasmin yields two intermediate fragments, X and Y. Fragment X is formed upon release of 
the carboxy terminal portion of the Aα-chain and the amino portion of the Bβ-chain. In this 
case the two distal domains of Fg remain connected by the central domain. But in fragment Y, 
only one distal domain is connected to the central domain. 
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Figure 6.  Schematic representation of plasmin- digested fibrinogen . A) The three polypeptides 
chains of Fg with respective cleavage sites for plasmin. The dark areas represent the regions 
including in the D fragment of fibrinogen. B) Fragment D and E form after plasmin cleavage. 
A 
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RESULTS AND DISCUSSION 
 
There are several secreted proteins from S. aureus that have affinity for fibrinogen, but their 
function are unclear since not all of them are involved in the bacterial attachment to the host. 
It is known that coagulase can convert fibrinogen to fibrin which can cover and protect 
staphylococci from the immune system. The function of the two remain extracellular 
fibrinogen-binding  proteins (Efb and 60 kDa protein) have not been determined and are the 
basis of the present investigation. 
 
Extracellular fibrinogen-binding protein (Efb) 
That Efb is a potential virulence factor is suggested by data showing that 1) the incidence of 
the efb gene and its protein is around 100% among clinical isolates (12), 2) this protein is 
produced in vivo (17) and 3) we have constructed an isogenic mutant defective in the efb gene 
to analyse the virulence of S. aureus in wound infections in the presence or absence of the Efb 
protein (I). With an experimental wound infection model in rats, we demonstrated that Efb 
contributes to the virulence of Staphylococcus aureus in this model. We also showed that 
twice as many animals challenged with the parenteral strain developed severe clinical signs of 
wound infection compared with those infected with the isogenic mutant. The different levels 
of severity between these two groups also resulted in differential  rates of weight loss. These 
results support previous data from a mouse mastitis model which was used to study the effect 
of vaccination with FgBP against staphylococcal infection (57). Vaccination with Efb reduced 
the rate of mastitis compared with controls vaccinated with collagen-binding protein. Since 
the mammary glands were traumatized during the procedure, this model mimics not only 
mastitis but also resembles a wound infection caused by S. aureus. A protective effect of anti-
Efb antibodies against wound infection is therefore likely. 
 
The fact that the antibody response to Efb was significantly lower in patients with 
staphylococcal infection compared to the normal population suggests that Efb may be a 
suitable agent for a vaccine against staphylococcal infection (17). It is also possible that 
passive immunization using anti Efb antibodies may provide protection against 
staphylococcal infection in patients with high susceptibility to infection as in 
immunocomprimised patients undergoing  surgery. 
 
The exact biological function of Efb in wound- or other infections is unclear, but it could be 
related to Fg-binding since fibrin is abundant in wounds and fibrinogen-/fibrin-binding  is the 
only known function of Efb. The function of Efb is not related to the adherence of the bacteria 
to fibrinogen because Efb is an extracellular protein and the ability of an efb negative mutant 
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to bind to immobilized Fg is unaltered (I). Probably, the binding of Efb to functional sites on 
fibrinogen  disturbes the healing process which could be beneficial for the bacteria (I). 
 
The mechanism of action of Efb can only be speculative, but we have demonstrated that there 
are multiple binding sites involved in the binding of Efb to fibrinogen (II). With two different 
fusion proteins containing different regions of the Efb molecule, it was shown that one 
binding site is located at the C - terminal region of Efb and the other binding domain is 
located at the two repeat region of the N - terminal portion of the molecule (Figure 7). This 
finding was later confirmed using synthetic peptides corresponding to different regions of the 
Efb molecule (III)(Figure 8).  Both peptides from the C-terminal portion of Efb (residues 91 - 
136) and peptides containing the second repeat of the N-terminal region of Efb bind strongly 
to soluble fibrinogen and they inhibit the Efb-fibrinogen interaction. Therefore, a singel Efb 
molecule is able to bind two fibrinogen molecules simultaneously. When these two proteins 
are mixed in equimolar concentrations, the Efb-fibrinogen complex precipitates (II). Whether 
or not such precipitation occurs in vivo and its possible functional significance are unknown.  
It should be re-emphasized that Efb is not coagulase and the precipitation of the Efb-Fg 
complex is different from coagulation caused by staphylocoagulase. However, Efb and 
coagulase share a degree of sequence homology. 
 
Paper IV shows that 1) the repeat region of Efb competes with the corresponding region of 
coagulase for the same binding domain on fibrinogen, 2) the binding of fibrinogen to an 
immobilized fusion protein containing the two repeats of Efb is blocked by the presence of 
coagulase and 3) the binding of Fg to immobilized coagulase is inhibited by the presence of 
Efb or its two repeat regions.  The binding similarity of Efb and coagulase is related to the 
high degree of homology between these two proteins. We have found that the homology of 
the second repeat region of Efb and the repeat region of coagulase is greater than the 
homology of the first repeat of Efb , with the repeats of coagulase (82% versus 53%)(Figure 
1).  Moreover, a putative Ca2+ binding site has been predicted at the second repeat of Efb, at 
residues 51-58 (E-F-N-D-G-T-F-E), which resembles an EF-hand motif (III). Several human 
proteins bind to Ca2+. Also proteins produced by S. aureus, such as Clf and Sdr can bind to 
Ca2+. 
The precipitation of the Efb-Fg complex from equimolar mixtures of these two proteins can 
be enhanced by the presence of Ca2+ or Zn2+, but not by Mg2+ (II). The binding of fibrinogen 
to 
immobilized Efb is increased by Ca2+ (III). Calcium is necessary for a number of biochemical 
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processes such as the formation of blood clots. It is likely that Ca2+ influences the affinity of 
Efb for Fg during infections caused by Staphylococcus aureus.  
  
In order to understand the function of FgBPs, it is important to know the binding epitopes on 
fibrinogen for staphylococcal proteins. This knowledge could lead to the development of new 
antistaphylococcal treatments and new vaccines. The binding domains for the different  
Figure 7. Identification of the 
fibrinogen-binding regions on Efb. 
A) Schematic model of Efb, GST-
RR (the two repeats (RR) of Efb 
fused with Glutathione-S-transferase 
(GST)) and Efb210 (N-terminal part 
of Efb fused with six consecutive 
histidine residues (6xHis)) . 
B) Capture ELISA of Fg. Binding of 
Fg to immobilized Efb, GST-RR  or 
Efb210 . 
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Figure 8. Binding of radiolabelled Efb peptides to soluble human fibrinogen (Wade et al., 
1998)(III). The filled  bars show the Efb peptides that bind to Fg to the greatest extent. 
 
 
fibrinogen-binding  proteins are distinct. Binding of ClfA takes place on the γ-chain of Fg, 
whereas ClfB binding takes place on both the Aα- and Bβ-chains. Efb does not interfere with 
the adherence of ClfA since ClfA inhibits up to 90% of the binding of Fg to immobilized Clf, 
while Efb has no effect (II).  In our investigation we found that the Efb protein interacts with 
the Aα-chain of fibrinogen, indicating that at least one of the binding sites for Efb is located 
at the Aα-chain (II and IV). More detailed analysis showed that the D fragment obtained 
from plasmic cleavage of fibrinogen retained the same binding properties to Efb characteristic 
of the complete Fg molecule (IV).  This indicates that Efb interacts with at least one of the 
polypeptides located on the D fragment. The D fragment includes three polypeptide fragments 
represented by bands on SDS-PAGE of  45 kDa for the Bβ-chain, 42 kDa for the γ-chain and 
a 14 kDa polypeptide from the Aα-chain. The Efb binding site on Fg is located between  
residues 105 and 197 of the Aα-chain of the D fragment. Binding of Efb to sites of functional 
importance on Fg may interfere with important physiological processes such as wound 
healing. Interestingly, several important functions have been attributed to the Aα- polypeptide 
chain of the D fragment or nearby regions. These functions that may be disturbed by the 
binding of Efb.   
 
i) An Arg-Gly-Asp (RGD) sequence which is conserved among several mammalian species is 
located at residues 95-97 (only some residues from the N-terminal end of the Aα-chain of the 
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D fragment) (30, 31). This RGD sequence is one of the regions on Fg recognised by platelet 
integrin GPIIb-IIIa. It is possible that Fg-GPIIb-IIIa binding is sterically hindered by the 
presence of the Efb. Another platelet binding site located at the C-terminal end of the γ-chain 
of Fg is recognised by ClfA but not by Efb. A recombinant protein containing residues 221-
550 of ClfA inhibits fibrinogen-dependent platelet aggregation and platelet adhesion to 
immobilized fibrinogen. Interestingly, three short regions in the Efb sequence are similar to 
three different regions of the glycoprotein GPIIIa (Figure 9). This observation should be the 
focus of further investigations on the biological functions of Efb.  None of the three regions of 
Efb or GPIIIa are involved in the fibrinogen-binding. We can not exclude, however, that Efb 
can interfer with other functions of integrin. For example, GPIIIa is present on endothelial 
cells as part of the vitronectin receptor. 
 
 
 
GPIIIa    19KPVS22----------265IVQPNDG271----------609TFKKE623 
Efb    11KPVS13-----------19IVEYNDG25------------75TIKKE79 
 
 
Figure 9.  Similarity between GPIIIa and Efb. 
 
 
ii) Thrombospondin is the most abundant protein component of the α-granula of platelets  
activated at the site injury. Thrombospondin binds to fibrinogen and to the platelet surface 
and thereby mediates irreversible platelet aggregation (91). Thrombospondin therefore helps 
to stabilize the adhesion of fibrinogen to activated platelets.  One of the thrombospondin-
binding sites is located at residues 113-126 of the Aα-chain of fibrinogen (4); a region that is 
included in the polypeptide recognised by Efb. 
 
iii) Plasminogen activation is catalyzed by a tissue-type plasminogen activator (t-PA). Fibrin 
and some fibrinogen degradation products such as fragment D but not intact fibrinogen 
accelerate the activation of plasmin by t-PA. More detailed studies revealed that an essential 
role is played by Aα148-161 in this process (95). Binding of Efb to this region probably 
inhibits the activation of plasminogen by t-PA thus disturbing the fibrinolytic pathway. 
 
Efb may also interfere with the conversion of Fg to fibrin or other functions of fibrinogen 
such as the interaction with endothelial cells and fibronectin.   
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In conclusion, Efb increases the virulence of S. aureus in wound infections. Efb blocks 
important functional sites on fibrinogen that may delay wound healing which could be 
beneficial for the bacteria.  
 
Extracellular adherence protein (Eap) 
In the second part of this thesis we characterized a 60 kDa fibrinogen-binding protein 
designated as Eap, extracellular adherence protein (V). In culture, Eap is a secreted protein 
since 70% of the total Eap is found in the growth medium compared with only 30 % on the 
cell surface. It is possible that the function of Eap is distinct from the function of other 
fibrinogen-binding proteins from S. aureus since Eap has a broader binding profile as 
indicated by the following observations (V): 
 
1) At least seven proteins from human plasma are enriched by an Eap-Sepharose column, 
including, prothrombin, fibronectin and  fibrinogen. However, Eap has a targeted specificity 
for these proteins since not every protein  from plasma bind to Eap. Human serum albumin, 
collagen type II and lysozyme do not interact with Eap in a capture ELISA, or in a western 
blot. 
 
2) Eap can form oligomers. Eap – Eap interactions were demonstrated by affinity 
chromatography using Eap-Sepharose where a  60 kDa protein was isolated from the 
supernate of an S. aureus culture. Morever, Eap spotted at various concentrations onto a 
nitrocellulose filter was detected by an iodinated Eap probe. 
  
3) Exogenously applied Eap interacts with the surface of Staphylococcus aureus. In studies 
examining the interaction of S. aureus and immobilized Fg, we found that while CflA 
inhibited bacterial binding to fibrinogen, Eap actually enhanced binding. The stimulation of 
the staphylococcal adherence by Eap led us to investigate the direct interaction between S. 
aureus an Eap. This finding was confirmed and extended by studies showing that soluble 
iodinated Eap could bind to S. aureus in a dose-dependent manner and that staphylococcal 
cells could adhere to immobilized Eap.  
 
The binding of an extracellular protein to the surface of bacteria was described previously in 
Listeria monocytogenes. Listeria expresses two kinds of internalin (InlA and InlB) which are 
required for bacterial entry into the host cell (13, 14). The surface-associated Internalin A has 
an LPTXG motif which anchors the protein to a peptidoglycan. But Internalin B which is 
mainly secreted lacks this motif. Like Eap, InlB binds to the bacterial surfaces when added 
exogenously (13, 14). Otherwise no other relationship between Eap and InlB has been noted. 
Eap also has the capacity to agglutinate bacterial cells. Due to its ability to form oligomers 
and to bind to cells of S. aureus, Eap was expected to cause aggregation. In fact, it has been 
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known for some time that S. aureus forms aggregates.  Which components on the bacterial 
surface are recognised by Eap is still unkwon. The number of binding sites per cell is very 
high indicating that components other than a protein receptor may be involved. 
  
The presence of Eap in solution stimulates the attachment of Staphylococcus aureus to 
epithelial cells and fibroblasts. It thus seems that Eap can act as a bridging molecule between 
the bacteria and the host cells. Which components of the host cell interact with Eap is unclear, 
but it is possible  that plasma proteins bound to integrin receptors might be recognised by 
Eap. In this situation, Eap might recognise fibronectin bound to integrin α5β1 on fibroblast 
cells.  
 
The amino- and carboxy-terminal sequences of Eap were analyzed to find similarities with a 
known sequence. The amino terminal sequence of Eap has a high degree of homology with 
the N-terminal sequence of the Map protein from S. aureus strain FDA574, major 
histocompatibility complex class II analogous protein (Figure 10). While the carboxy terminal 
sequence of Eap is different from that of Map,  the C-terminal sequence of Efb is identical to 
the C-terminal of Map from strain Newman (unpublished sequence, partial sequence EMBL 
accession nr. 4138456). Map has been described as a surface-associated protein lacking an 
LPTXG sequence (38). The percentage of the total Map produced by S. aureus that is located 
in the culture supernatant or on the cell-surface has not been described previously. Similar to 
Eap, Map has a broad binding profile and interactes with several plasma and matrix proteins 
(34).  
 
A 100% homology was found between the amino- and carboxy-terminal sequences of Eap 
with the N- and C-terminal sequences of a 70 kDa protein previously described by Yousif and 
coworkers (p70) (24, 98) (unpublished sequence, EMBL, accession nr. Y10419). 
Furthermore, The entire amino acid sequence of p70 is highly homologous (74%) to the 
sequence of Map. The homology between the region located between residues 1 to 540 of 
Map and the corresponding region on p70 is 84% while the rest of the amino acid sequence 
shares only 27% similarity (Figure 10). This indicates that p70 is similar to Map and may 
belong to a family of related proteins. It is possible that Eap may be related to p70 and Map. 
The observation that Eap is secreted while the another proteins are not, may be a strain 
variation. 
 
p70 belongs to a group of proteins described as highly cationic staphylococcal proteins due to 
their extreme isolectric point of 10 (100). p70 like a 32 kDa neutral phosphatase (NPtase) 
interacts with immunoglobulin without a specific antigen-antibody recognition.  We have 
noted a nonspecific interaction between Eap and immunoglobulin during capture ELISA. It 
has been shown that both the 32 kDa protein and p70 bind to the glomerular basement 
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membrane (GBM) of rats. These proteins may be involved in glomerular injury in 
glomerulonephritis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Similarity between Map, p70 and Eap. A) Schematic drawing of Map from S. 
aureus strain Newman and  FDA574 and p70 protein from strain Wood-46. Map consist of a 
signal sequence (S) (not included in our picture) followed by a unique sequence (U) and 
several repeated domains (R). The percent homology between the sequences of Map from 
different strains are indicated. B) Comparison of the N- and C-terminal sequences of Eap, 
Map and p70. 
 
 
 (24, 99). This suggests that p70 (and Eap) has the ability to bind to the extracellular matrix 
located in the GBM.  
 
In conclusion, we have characterized an extracellular protein that possesses both broad 
binding specificity to matrix and plasma proteins, and the capacity to recognize bacterial cell 
surfaces. We proposed a mechanism of adherence enhancement of S. aureus to host 
components stimulated by Eap.  
  
Eap  (Newman)     AAKPLDKSS--------------------------------------------------SKKNK  
Map (Newman)      ----------------------------------------------------------- QYTKSKKNK 
Map (FDA574)       AAKQIDKSSS-------------------------------------------- -KVDIEIKF 
p70  (Wood-46)     AAKPLDKSSS---------------------------------------------TKSKKNK 
B 
A 
 U    R      R      R      R      R      R 
    
84%           homology         27% 
  
  
90%           homology          
  
Map  (Newman) 
Map  (FDA574) 
p70  (Wood-46) 
FIBRINOGEN-BINDING PROTEINS FROM STAPHYLOCOCCUS AUREUS                                                              41
SUMMARY 
 
An extracellular fibrinogen-binding protein (Efb) from Staphylococcus  aureus: 
* contributes to the virulence of Staphylococcus aureus in wound infections  
* binds to sites of functional importance on the Aα-chain of fibrinogen such as regions close 
to the Arg-Gly-Asp (RGD) sequence and to the thrombospondin-binding site. This may 
interfere with platelet binding to fibrinogen. 
*contains two binding sites for fibrinogen-binding. One binding site is located at C terminus 
of Efb and the other is located at the two repeat regions of the N terminus. 
 
An extracellular adherence protein (Eap) from Staphylococcus aureus: 
* has a broad binding profile. Eap binds to at least seven plasma proteins, including 
fibrinogen, prothrombin and fibronectin. 
* stimulates attachment of S. aureus to host cells. This may represent a novel mechanism for 
the adherence of S. aureus to host components. 
* Is similar and may be related to Map and p70 protein from S. aureus. In contrast to Map and 
p70, Eap is secreted. 
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